Back to Search

MARK PASMANTIER, MD

MD

Hematology & Oncology Physician

NPI: 1558430199Individual

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

98988(NY)

Research & Publications (17)

Thalidomide and rituximab in Waldenstrom macroglobulinemia.
PMID 18713945·Blood·2008
3-trial
Survival of patients with stage I lung cancer detected on CT screening.
PMID 17065637·N Engl J Med·2006
4-observational
CT screening for lung cancer: the value of short-term CT follow-up.
PMID 16608955·Chest·2006
8-other
Managing the small pulmonary nodule discovered by CT.
PMID 15078769·Chest·2004
4-observational
CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans.
PMID 14990809·Radiology·2004
4-observational
Overdiagnosis in chest radiographic screening for lung carcinoma: frequency.
PMID 12599235·Cancer·2003
8-other
Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
PMID 14666040·J Thorac Cardiovasc Surg·2003
3-trial
Tumor size predicts survival within stage IA non-small cell lung cancer.
PMID 14605056·Chest·2003
8-other
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
PMID 12860939·J Clin Oncol·2003
3-trial
Guidelines for the use of spiral computed tomography in screening for lung cancer.
PMID 12572701·Eur Respir J Suppl·2003
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
407 E 70TH ST, 3RD FLOOR
NEW YORK, NY 10021

Quick Facts

NPI
1558430199
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
17

Are you this provider?

Claim Your Profile